All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

This phase 3 clinical trial is looking at better ways to treat advanced liver cancer, also known as hepatocellular carcinoma. Researchers want to compare a pair of immune-boosting drugs, nivolumab and ipilimumab, against standard daily tablet treatments called sorafenib or lenvatinib. Immunotherapy works by helping your own body's immune system recognise and attack cancer cells. In this study, people who have not yet had treatment for advanced liver cancer will be placed into one of two groups by chance. One group receives the immunotherapy combination through a drip, while the other takes standard tablet medication. The main goal is to find out if the immunotherapy combination helps patients live longer than the standard treatments. Researchers will also check whether the tumours shrink, how long the treatments keep the cancer under control, and how each option affects your day-to-day quality of life.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Bristol-Myers Squibb Services Unlimited Company
Enrolment target
370
Start
27 Feb 2024

What is this study about?

Hepatocellular carcinoma is the most common type of primary liver cancer. When it is found at an advanced stage, it cannot be cured with surgery alone. In these cases, doctors usually prescribe targeted drugs taken as daily tablets, such as sorafenib or lenvatinib. While these medicines can help slow the cancer down, doctors are looking for more effective options that give people more time and a better quality of life.

This trial investigates a different approach using immunotherapy. Immunotherapy uses your body's own natural defences to fight the cancer. This study combines two different immunotherapy medicines called nivolumab and ipilimumab. Together, they aim to 'take the brakes off' your immune system so it can search for and destroy liver cancer cells more effectively.

Because this is a Phase 3 trial, it is one of the final stages of research before a new treatment can become widely available on the NHS. By comparing the new combination directly against the current standard tablets, researchers can clearly see which treatment works better. The results could help change how advanced liver cancer is treated in the UK and around the world.

Key takeaways

  • Tests a two-drug immunotherapy drip against standard daily tablets for advanced liver cancer.
  • Aimed at adults who have not yet had systemic drug treatment for their liver cancer.
  • A computer decides by chance which of the two treatments you will receive.
  • The main aim is to see if immunotherapy helps people live longer with a good quality of life.
  • You can leave the study at any time without it affecting your standard NHS care.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with advanced liver cancer that cannot be removed with surgery. To take part, you must not have had any previous drug treatments for your advanced liver cancer, as researchers are testing these medicines as a first-choice option.

You will need to be reasonably well in your everyday life and have liver function that is stable enough to safely handle the trial medicines. A doctor will check your overall fitness and run standard blood tests to make sure of this.

You may not be eligible if you have other serious health problems, such as severe autoimmune conditions where the immune system attacks healthy tissue, or active infections that could make immunotherapy unsafe. Your medical team will review your full health history to ensure taking part is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with advanced liver cancer (hepatocellular carcinoma).
  3. I have not yet received drug treatment for this advanced stage of cancer.
  4. I am well enough to carry out basic daily tasks independently.
  5. I am willing to travel to the hospital for regular treatment visits and scans.
Answer every question to see your result.

What does participation involve?

If you join this study, a computer will place you into one of two treatment groups at random. This means neither you nor your doctor can choose which treatment you receive. One group will receive the immunotherapy drugs through a drip directly into a vein at a hospital clinic. The other group will take standard targeted cancer medicine as tablets by mouth at home.

You will need to visit the hospital clinic regularly for health checks, blood tests, and treatment sessions. Every few months, you will have imaging scans, such as CT or MRI scans, to see how your liver tumour is responding. You will also be asked to fill in simple questionnaires about your symptoms and how you are feeling day to day.

You will stay on your assigned treatment for as long as it is helping you and the side effects remain manageable. After you finish the treatment, the study team will continue to stay in touch with you for regular follow-up checks to monitor your health over the long term.

Potential risks and benefits

Taking part in this study may help shrink your tumour or help you live longer, although there is no guarantee that the treatments will work for you personally. The findings will also help doctors improve care for people with liver cancer in the future. However, all cancer treatments carry a risk of side effects. Immunotherapy can cause your immune system to attack healthy parts of your body, leading to problems such as severe tiredness, skin rashes, gut irritation, or inflammation in your organs. The standard tablets can cause high blood pressure, fatigue, or sore skin on your hands and feet. You are entirely free to leave the trial at any time without giving a reason, and your regular NHS medical care will continue as normal.

Locations (8)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Belgium
  • —
    Unverified
    Poland
  • —
    Unverified
    France
  • —
    Unverified
    Spain
  • —
    Unverified
    Romania
  • —
    Unverified
    Italy
  • —
    Unverified
    Germany
  • —
    Unverified
    Austria

Common questions

What is a Phase 3 clinical trial?

A Phase 3 trial compares a new treatment with the current standard treatment in a large group of people to confirm whether the new option is more effective and safe.

How will I receive the study medicines?

Depending on which group you are placed in, you will either receive immunotherapy through a drip in a hospital clinic or take targeted tablets at home every day.

Can I choose which treatment group I join?

No. A computer assigns you to a group by chance. This process is called randomisation and helps ensure the study results are fair and reliable.

Do I have to pay to take part in the trial?

No. The trial medicines and tests are provided free of charge, and some studies may also help cover your travel costs to and from the hospital.

What happens if my cancer gets worse during the study?

If your scans show that the cancer is growing or if side effects become too troublesome, your doctor will stop the trial treatment and discuss other care options with you.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Niv…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.